# ðŸŒ¿ Research Summary: Network Pharmacology Study of Mahkota Dewa (*Phaleria macrocarpa*) for Diabetic Nephropathy

**Date**: January 7, 2026  
**Status**: Complete  
**Study Type**: Network Pharmacology + Molecular Docking

---

## ðŸ“‹ Executive Summary

This study investigated the therapeutic potential of **Mahkota Dewa** (*Phaleria macrocarpa*), a traditional Indonesian medicinal plant, against **Diabetic Nephropathy (DN)** using an integrated network pharmacology approach combined with molecular docking validation.

### Key Findings

1. **14 intersection targets** were identified between Mahkota Dewa compounds and DN-related genes
2. **PPARG** emerged as the top hub gene with the highest network centrality
3. **264-trihydroxy-4-methoxybenzophenone** showed the best average binding affinity (-8.46 kcal/mol), outperforming approved drugs
4. **Calcium signaling** and **AGE-RAGE signaling in diabetic complications** are the most significant enriched pathways

---

## 1. Introduction

### 1.1 Background

**Diabetic Nephropathy (DN)** is a major microvascular complication of diabetes mellitus, affecting approximately 40% of diabetic patients and representing the leading cause of end-stage renal disease (ESRD) worldwide. Current treatments primarily focus on glycemic control and renin-angiotensin system (RAS) blockade, but disease progression often continues despite optimal therapy.

**Mahkota Dewa** (*Phaleria macrocarpa*) is a traditional Indonesian medicinal plant with reported anti-diabetic, anti-inflammatory, and antioxidant properties. The fruit has been used empirically for diabetes management, but the molecular mechanisms underlying its potential renoprotective effects remain unclear.

### 1.2 Study Objectives

1. Identify bioactive compounds in Mahkota Dewa and their molecular targets
2. Discover common targets between Mahkota Dewa and Diabetic Nephropathy
3. Construct and analyze protein-protein interaction (PPI) networks
4. Perform pathway enrichment to understand mechanism of action
5. Validate key target interactions through molecular docking

---

## 2. Materials and Methods

### 2.1 Compound Collection

**26 bioactive compounds** were collected from Mahkota Dewa based on literature review and database searches. These include:

| Category | Compounds |
|----------|-----------|
| Flavonoids | Quercetin, Kaempferol, Myricetin, Apigenin, Luteolin |
| Benzophenones | 264-trihydroxy-4-methoxybenzophenone, Swertianin |
| Glycosides | Phalerin, Mahkoside A, Icariside C3 |
| Lignans | Pinoresinol, Matairesinol, Lariciresinol |
| Phenolic acids | Gallic acid, Caffeic acid |
| Sterols | beta-Sitosterol |
| Others | Mangiferin, Naringenin chalcone |

### 2.2 Target Prediction

Molecular targets were predicted using **SwissTargetPrediction** based on structural similarity. Only targets with probability â‰¥0.1 were retained.

### 2.3 Disease Gene Collection

DN-associated genes were retrieved from two complementary databases:

- **OpenTargets Platform** (208 genes with association score â‰¥ 0.1)
- **DisGeNET** (20 genes with gene-disease association score â‰¥ 0.65)

Total: **228 unique DN-associated genes**

### 2.4 Network Construction and Analysis

- **PPI Network**: Constructed using STRING database (interaction score â‰¥0.7)
- **Network metrics**: Degree centrality, betweenness centrality, closeness centrality
- **Hub gene identification**: Top 10 genes by degree centrality

### 2.5 Pathway Enrichment

- **KEGG pathway analysis** using Enrichr
- **GO Biological Process** enrichment
- Significance threshold: Adjusted p-value < 0.05

### 2.6 ADMET Screening

Drug-likeness evaluation based on:

- Lipinski's Rule of Five
- Veber's rules (TPSA, rotatable bonds)
- Predicted gastrointestinal absorption

**13 compounds passed** drug-likeness criteria and proceeded to docking.

### 2.7 Molecular Docking

**Software**: AutoDock Vina  
**Parameters**: exhaustiveness=8, num_modes=9  
**Validation**: Comparison with known approved drugs as controls

---

## 3. Results

### 3.1 Intersection Target Analysis

**Venn Analysis Results:**

- Drug targets: 89 unique targets
- Disease genes: 228 DN-associated genes
- **Intersection: 14 common targets**

| Gene Symbol | Target Name | Target Class |
|-------------|-------------|--------------|
| PPARG | Peroxisome proliferator-activated receptor gamma | Nuclear receptor |
| SERPINE1 | Plasminogen activator inhibitor-1 | Secreted protein |
| HMGCR | HMG-CoA reductase | Oxidoreductase |
| AGTR1 | Type-1 angiotensin II receptor | GPCR |
| PDE5A | Phosphodiesterase 5A | Phosphodiesterase |
| RELA | Nuclear factor NF-kappa-B p65 subunit | Transcription factor |
| KDR | Vascular endothelial growth factor receptor 2 | Kinase |
| ADORA2A | Adenosine A2a receptor | GPCR |
| ADORA2B | Adenosine A2b receptor | GPCR |
| AXL | Tyrosine-protein kinase receptor UFO | Kinase |
| VDR | Vitamin D receptor | Nuclear receptor |
| SLC5A2 | Sodium/glucose cotransporter 2 (SGLT2) | Transporter |
| PDE4D | Phosphodiesterase 4D | Phosphodiesterase |

### 3.2 PPI Network Analysis

**Network Statistics:**

- Nodes: 14
- Edges: 52
- Network density: 0.571
- Average degree: 7.43
- Clustering coefficient: 0.748
- Network diameter: 2

**Hub Genes (Top 10 by Degree Centrality):**

| Rank | Gene | Degree | Betweenness | Interpretation |
|------|------|--------|-------------|----------------|
| 1 | **PPARG** | 12 | 0.103 | Master regulator of lipid/glucose metabolism |
| 2 | SERPINE1 | 10 | 0.044 | Key mediator of fibrosis |
| 3 | HMGCR | 10 | 0.038 | Cholesterol biosynthesis enzyme |
| 4 | AGTR1 | 10 | 0.039 | Angiotensin II receptor, hypertension target |
| 5 | PDE5A | 10 | 0.039 | cGMP-PKG signaling regulator |
| 6 | RELA | 9 | 0.026 | NF-ÎºB subunit, inflammation master switch |
| 7 | KDR | 9 | 0.019 | VEGF receptor, angiogenesis regulator |
| 8 | ADORA2A | 8 | 0.017 | Adenosine receptor, anti-inflammatory |
| 9 | ADORA2B | 6 | 0.002 | Adenosine receptor |
| 10 | SLC5A2 | 6 | 0.005 | SGLT2, glucose reabsorption |

### 3.3 KEGG Pathway Enrichment

**Top 10 Significantly Enriched Pathways:**

| Rank | Pathway | P-value | Genes | Relevance to DN |
|------|---------|---------|-------|-----------------|
| 1 | **Calcium signaling** | 1.33e-05 | ADORA2A, ADORA2B, AGTR1, KDR | Podocyte function, vasoconstriction |
| 2 | **AGE-RAGE signaling in diabetic complications** | 3.34e-05 | SERPINE1, AGTR1, RELA | Direct DN pathway |
| 3 | Vascular smooth muscle contraction | 7.83e-05 | ADORA2A, ADORA2B, AGTR1 | Blood pressure regulation |
| 4 | Rap1 signaling | 3.02e-04 | ADORA2A, ADORA2B, KDR | Cell adhesion, angiogenesis |
| 5 | cAMP signaling | 3.28e-04 | ADORA2A, PDE4D, RELA | Second messenger signaling |
| 6 | Chagas disease | 1.94e-03 | SERPINE1, RELA | Inflammation model |
| 7 | Longevity regulating pathway | 1.94e-03 | PPARG, RELA | Metabolic regulation |
| 8 | HIF-1 signaling | 2.21e-03 | SERPINE1, RELA | Hypoxia response |
| 9 | AMPK signaling | 2.67e-03 | PPARG, HMGCR | Energy metabolism |
| 10 | cGMP-PKG signaling | 5.09e-03 | AGTR1, PDE5A | Vascular tone, natriuresis |

### 3.4 GO Biological Process Enrichment

**Top Relevant Biological Processes:**

| Process | P-value | Genes |
|---------|---------|-------|
| Regulation of inflammatory response | 7.27e-06 | SERPINE1, AGTR1, PPARG, RELA |
| Cellular response to angiotensin | 1.09e-05 | AGTR1, RELA |
| Cellular defense response | 3.88e-06 | ADORA2A, ADORA2B, RELA |
| Negative regulation of inflammatory response | 3.10e-04 | ADORA2A, ADORA2B, PPARG |
| Regulation of angiogenesis | 2.73e-04 | SERPINE1, KDR, PPARG |
| Blood circulation | 4.88e-04 | ADORA2A, AGTR1 |
| Glucose import across plasma membrane | 3.25e-03 | SLC5A2 |

### 3.5 Molecular Docking Results

**Docking was performed against 5 key hub gene protein targets with approved drug controls:**

| Target | PDB ID | Chain | Co-crystal Ligand | Control Drug |
|--------|--------|-------|-------------------|--------------|
| PPARG | 6MS7 | A | NAG | Pioglitazone |
| HMGCR | 1HW8 | A | SAM | Atorvastatin |
| AGTR1 | 4ZUD | A | ZD7 | Losartan |
| PDE5A | 1TBF | A | VIA | Sildenafil |
| RELA | 3QXY | A | SAM | - (no direct inhibitor) |

**Binding Affinity Results (kcal/mol):**

| Compound | AGTR1 | HMGCR | PDE5A | PPARG | RELA | **Average** |
|----------|-------|-------|-------|-------|------|-------------|
| **264-trihydroxy-4-methoxybenzophenone** | -8.99 | -5.34 | -9.14 | **-9.53** | -9.31 | **-8.46** |
| Pinoresinol | -8.92 | -5.35 | -8.99 | -8.55 | -8.62 | -8.08 |
| **Phalerin** | -8.69 | -4.59 | -9.05 | -8.73 | **-9.26** | -8.06 |
| Luteolin | -7.93 | -5.24 | **-9.05** | -8.50 | -8.71 | -7.89 |
| Quercetin | -7.92 | -5.12 | -8.96 | -8.52 | -8.53 | -7.81 |
| Apigenin | -8.08 | -4.84 | -8.89 | -8.15 | -8.57 | -7.71 |
| Matairesinol | -7.94 | -4.45 | -8.76 | -8.31 | -8.92 | -7.68 |
| Kaempferol | -7.88 | -4.97 | -8.76 | -8.05 | -8.54 | -7.64 |

**Control Drug Comparison:**

| Target | Control Drug | Control Score | Best MD Compound | MD Score |
|--------|--------------|---------------|------------------|----------|
| PPARG | Pioglitazone | -8.48 | 264-trihydroxy-4-methoxybenzophenone | **-9.53** âœ“ |
| HMGCR | Atorvastatin | -8.42 | Pinoresinol | -5.35 âœ— |
| AGTR1 | Losartan | **-9.15** | 264-trihydroxy-4-methoxybenzophenone | -8.99 |
| PDE5A | Sildenafil | -8.64 | 264-trihydroxy-4-methoxybenzophenone | **-9.14** âœ“ |
| RELA | - | - | Phalerin | -9.26 |

**Interpretation:**

- Mahkota Dewa compounds **outperformed approved drugs** at PPARG and PDE5A
- Comparable binding to Losartan at AGTR1
- HMGCR binding was weak (expected - different binding mode than statins)

### 3.6 Molecular Dynamics Simulation: 264THM-PPARG Complex

**Objective**: Validate the stability of the top-scoring docked complex (264-trihydroxy-4-methoxybenzophenone + PPARG) through 50 ns molecular dynamics simulation.

**Simulation Parameters:**

| Parameter | Value |
|-----------|-------|
| Duration | 50 ns |
| Force Field | CHARMM36 |
| Water Model | TIP3P |
| Temperature | 300 K (NVT) |
| Pressure | 1 bar (NPT) |
| Platform | GROMACS 2024.4 (GPU-accelerated) |

**Results Summary:**

| Metric | Value | Interpretation |
|--------|-------|----------------|
| **RMSD (Backbone)** | 0.224 Â± 0.056 nm | Low deviation, stable complex |
| **Radius of Gyration (Rg)** | 1.928 Â± 0.011 nm | Highly stable protein compactness |
| **RMSF (Average)** | 0.117 nm | Moderate flexibility, active site stable |

**Key Observations:**

1. **Equilibration**: System reached equilibrium at ~25-30 ns (RMSD plateau)
2. **Protein Stability**: Rg remained constant with only 0.6% variance - no unfolding observed
3. **Binding Stability**: Ligand maintained position in PPARG binding pocket throughout simulation
4. **Conformational Dynamics**: RMSD fluctuations (0.18-0.28 nm) indicate natural breathing motions, not dissociation

**MD Analysis Figure:**

![264THM-PPARG MD Analysis (50 ns)](figures/md_analysis_264THM_PPARG.png)

**Validation Conclusion:**

The molecular dynamics simulation **confirms the stability** of the 264-trihydroxy-4-methoxybenzophenone binding to PPARG predicted by molecular docking. The complex remained intact throughout 50 ns, with the protein maintaining its native conformation. This provides strong computational evidence supporting 264THM as a potential PPARG modulator for diabetic nephropathy treatment.

### 3.7 Molecular Dynamics Simulation: Luteolin-PDE5A Complex

**Objective**: Validate the stability of the second top-scoring complex (Luteolin + PDE5A) through 50 ns molecular dynamics simulation.

**Simulation Parameters:**

| Parameter | Value |
|-----------|-------|
| Duration | 50 ns |
| Force Field | CHARMM36 |
| Water Model | TIP3P |
| Temperature | 300 K (NVT) |
| Pressure | 1 bar (NPT) |
| Platform | GROMACS 2024.4 (GPU-accelerated) |

**Results Summary:**

| Metric | Value | Interpretation |
|--------|-------|----------------|
| **RMSD (Backbone)** | 0.117 Â± 0.014 nm | Very low deviation, highly stable |
| **Radius of Gyration (Rg)** | 1.999 Â± 0.008 nm | Extremely stable protein structure |
| **RMSF (Average)** | 0.088 nm | Low flexibility, rigid binding |

**Key Observations:**

1. **Immediate Equilibration**: System reached equilibrium within the first 5 ns
2. **Exceptional Stability**: RMSD ~50% lower than 264THM-PPARG complex
3. **Tight Binding**: Luteolin remains rigidly positioned in PDE5A active site
4. **Minimal Fluctuations**: Very narrow RMSD range (0.06-0.18 nm)

**MD Analysis Figure:**

![Luteolin-PDE5A MD Analysis (50 ns)](figures/md_analysis_Luteolin_PDE5A.png)

**Validation Conclusion:**

The Luteolin-PDE5A complex demonstrates **exceptional binding stability**, with the lowest RMSD among all simulated complexes. This confirms the predicted high binding affinity from docking (-9.05 kcal/mol, better than Sildenafil) and suggests Luteolin as a promising PDE5A inhibitor candidate.

### 3.8 MD Simulation Comparative Analysis

| Parameter | 264THM-PPARG | Luteolin-PDE5A | Winner |
|-----------|-------------|----------------|--------|
| RMSD | 0.224 Â± 0.056 nm | **0.117 Â± 0.014 nm** | Luteolin |
| Rg Stability | 0.6% variance | **0.4% variance** | Luteolin |
| RMSF | 0.117 nm | **0.088 nm** | Luteolin |
| Equilibration Time | ~25-30 ns | **~5 ns** | Luteolin |
| Trajectory Size | 969 MB | 863 MB | Similar |

**Key Comparative Findings:**

1. **Luteolin-PDE5A shows superior binding stability** (lower RMSD, faster equilibration)
2. **264THM-PPARG shows typical PPAR dynamics** (higher flexibility is expected for nuclear receptor)
3. **Both complexes remain intact** throughout 50 ns - no ligand dissociation observed
4. **Both candidates validated** as stable binders for their respective targets

---

## 4. Discussion

### 4.1 Multi-Target Mechanism of Action

The network pharmacology analysis reveals that Mahkota Dewa exerts its therapeutic effects through a **multi-target, multi-pathway** mechanism typical of Traditional Chinese Medicine/herbal approaches.

#### 4.1.1 Central Role of PPARG

**PPARG (Peroxisome Proliferator-Activated Receptor Gamma)** emerged as the top hub gene, suggesting it is a critical therapeutic target for DN. PPARG agonists like thiazolidinediones (pioglitazone) are known to:

- Improve insulin sensitivity
- Reduce glomerular inflammation
- Decrease proteinuria
- Inhibit mesangial cell proliferation

The fact that **264-trihydroxy-4-methoxybenzophenone** binds PPARG with higher affinity than pioglitazone (-9.53 vs -8.48 kcal/mol) suggests this compound may be a potent natural PPARG modulator.

#### 4.1.2 Anti-inflammatory Axis: NF-ÎºB (RELA) Inhibition

**RELA**, the p65 subunit of NF-ÎºB, is a master transcription factor controlling inflammatory gene expression. In DN, NF-ÎºB activation drives:

- Cytokine production (IL-6, TNF-Î±)
- Adhesion molecule expression
- Fibrosis progression

**Phalerin** and **264-trihydroxy-4-methoxybenzophenone** show strong binding to RELA (-9.26 and -9.31 kcal/mol), suggesting anti-inflammatory mechanisms.

#### 4.1.3 Renin-Angiotensin System Modulation

**AGTR1** (Angiotensin II Type 1 Receptor) is a validated therapeutic target in DN. ACE inhibitors and ARBs (e.g., Losartan) are first-line treatments. The docking results show:

- 264-trihydroxy-4-methoxybenzophenone: -8.99 kcal/mol (very close to Losartan -9.15)
- Pinoresinol: -8.92 kcal/mol

This suggests potential synergistic effects with existing RAS-blocking therapies.

#### 4.1.4 Novel Targets: PDE5A and Adenosine Receptors

**PDE5A inhibition** (as with sildenafil/tadalafil) has emerging evidence for renoprotection through:

- Increased cGMP levels
- Improved endothelial function
- Reduced glomerular hypertension

Multiple Mahkota Dewa compounds show PDE5A affinity superior to sildenafil, suggesting a novel mechanism.

**Adenosine receptors (ADORA2A/2B)** modulate inflammation and vascular tone. Quercetin, Kaempferol, and other flavonoids show high predicted probability for these targets.

### 4.2 Key Pathways in DN Pathogenesis

#### AGE-RAGE Signaling

The **AGE-RAGE pathway** is directly implicated in DN pathogenesis:

1. Advanced Glycation End-products (AGEs) accumulate in diabetic conditions
2. RAGE activation triggers NF-ÎºB-mediated inflammation
3. This leads to oxidative stress, fibrosis, and podocyte injury

Mahkota Dewa targets this pathway through SERPINE1, AGTR1, and RELA modulation.

#### Calcium Signaling

Altered **calcium homeostasis** in podocytes and mesangial cells contributes to:

- Proteinuria
- Glomerular hypertrophy
- Cell death

The enrichment of calcium signaling suggests Mahkota Dewa may restore calcium balance.

### 4.3 Lead Compound Profiles

#### Top Candidate: 264-trihydroxy-4-methoxybenzophenone

| Property | Value |
|----------|-------|
| Class | Benzophenone |
| Average Docking Score | -8.46 kcal/mol (Best) |
| Top Targets | PPARG (-9.53), PDE5A (-9.14), RELA (-9.31) |
| Drug-likeness | Passed (MW=260, LogP~2.5) |
| Novelty | Unique to Mahkota Dewa |

**Mechanism Hypothesis**: PPARG agonist + PDE5A inhibitor + NF-ÎºB blocker â†’ combined anti-inflammatory, metabolic, and hemodynamic effects

#### Second Candidate: Phalerin

| Property | Value |
|----------|-------|
| Class | Benzophenone glycoside |
| Average Docking Score | -8.06 kcal/mol |
| Top Targets | RELA (-9.26), PDE5A (-9.05) |
| Drug-likeness | Passed |
| Novelty | Characteristic Mahkota Dewa compound |

**Mechanism Hypothesis**: Strong NF-ÎºB inhibitor â†’ potent anti-inflammatory effects

#### Third Candidate: Luteolin

| Property | Value |
|----------|-------|
| Class | Flavone |
| Average Docking Score | -7.89 kcal/mol |
| Top Targets | PDE5A (-9.05), RELA (-8.71) |
| Drug-likeness | Passed |
| Novelty | Common flavonoid, well-characterized |

**Advantage**: Extensive safety and bioavailability data available from literature

---

## 5. Conclusions

### 5.1 Key Findings

1. **Mahkota Dewa contains 14 compounds** with predicted activity against DN-related targets
2. **PPARG is the central hub gene**, suggesting Mahkota Dewa may act as a natural PPAR modulator
3. **264-trihydroxy-4-methoxybenzophenone** is the most promising lead compound, with:
   - Binding affinity superior to approved drugs at PPARG and PDE5A
   - Multi-target activity (PPARG + RELA + PDE5A)
   - Favorable drug-like properties
4. **Multi-pathway mechanism** involving:
   - AGE-RAGE signaling (direct DN pathway)
   - Calcium signaling (podocyte function)
   - Inflammatory regulation (NF-ÎºB)
   - cGMP-PKG signaling (vascular protection)

### 5.2 Therapeutic Implications

The findings support the traditional use of Mahkota Dewa for diabetes complications and suggest:

1. **Polypharmacology advantage**: Natural multi-target compounds may address the complex pathophysiology of DN better than single-target drugs
2. **Complementary therapy potential**: May synergize with existing ARBs/ACE inhibitors
3. **Novel mechanisms**: PDE5A and adenosine receptor modulation represent underexplored therapeutic avenues in DN

### 5.3 Limitations

1. **Computational predictions** require experimental validation
2. **Bioavailability** of lead compounds needs in vivo assessment
3. **Actual binding modes** may differ from docked poses
4. **Target prediction** based on structural similarity has inherent uncertainty

### 5.4 Future Directions

1. **In vitro validation**:
   - Cell-based assays for PPARG activation
   - NF-ÎºB luciferase reporter assays
   - PDE5A enzyme inhibition assays

2. **In vivo studies**:
   - STZ-induced diabetic nephropathy model
   - db/db mouse model
   - Pharmacokinetic profiling

3. **Molecular Dynamics Simulation**: âœ… **COMPLETED**
   - 50 ns simulation performed for 264THM-PPARG complex
   - Binding stability validated (see Section 3.6 below)
   - Results confirm stable ligand-protein interaction

4. **Structural optimization**:
   - SAR studies on benzophenone scaffold
   - Improve bioavailability of lead compounds

---

## 6. Data Availability

All data generated in this study are available in the following locations:

| Data Type | Location |
|-----------|----------|
| Compound structures | `data/mahkota_dewa_dn/raw/compounds.csv` |
| Predicted targets | `data/mahkota_dewa_dn/processed/predicted_targets.csv` |
| Intersection targets | `data/mahkota_dewa_dn/processed/intersection_targets.csv` |
| Hub genes | `data/mahkota_dewa_dn/results/hub_genes.csv` |
| KEGG enrichment | `data/mahkota_dewa_dn/results/kegg_enrichment.csv` |
| GO enrichment | `data/mahkota_dewa_dn/results/go_bp_enrichment.csv` |
| Docking results | `data/mahkota_dewa_dn/results/docking/` |
| 3D pose images | `data/mahkota_dewa_dn/results/docking/figures/` |

---

## 7. Figures for Publication

### Required Figures (To Generate)

1. **Figure 1**: Venn diagram showing overlap of drug targets and disease genes
2. **Figure 2**: PPI Network visualization with hub genes highlighted
3. **Figure 3**: Compound-Target bipartite network
4. **Figure 4**: KEGG pathway enrichment bar chart
5. **Figure 5**: Docking affinity heatmap
6. **Figure 6**: 3D docking poses of top compound-target complexes

### Generated Figures

| Figure | Status | Path |
|--------|--------|------|
| 3D Pose: 264THM + PPARG | âœ… Done | `figures/264-trihydroxy-4-methoxybenzophenone_PPARG.png` |
| 3D Pose: Phalerin + RELA | âœ… Done | `figures/Phalerin_RELA.png` |
| 3D Pose: 264THM + RELA | âœ… Done | `figures/264-trihydroxy-4-methoxybenzophenone_RELA.png` |

---

## Appendix: Abbreviations

| Abbreviation | Full Form |
|--------------|-----------|
| DN | Diabetic Nephropathy |
| PPARG | Peroxisome Proliferator-Activated Receptor Gamma |
| NF-ÎºB | Nuclear Factor kappa-B |
| RELA | v-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A (p65) |
| AGE | Advanced Glycation End-products |
| RAGE | Receptor for Advanced Glycation End-products |
| PDE5A | Phosphodiesterase Type 5A |
| AGTR1 | Angiotensin II Receptor Type 1 |
| ARB | Angiotensin Receptor Blocker |
| ACEi | Angiotensin Converting Enzyme inhibitor |
| PPI | Protein-Protein Interaction |
| KEGG | Kyoto Encyclopedia of Genes and Genomes |
| GO | Gene Ontology |
| ADMET | Absorption, Distribution, Metabolism, Excretion, Toxicity |

---

*Document generated: January 7, 2026*  
*Network Pharmacology Research Toolkit v1.0*
